CIRSE Registry for Emprint Microwave Ablation
CIEMAR is a European-wide, prospective, observational (non-interventional) study that will gather data on microwave ablation of colorectal liver metastases using the EMPRINT microwave ablation device. Microwave tumour ablation provides a minimally invasive, potentially curative treatment option for various neoplasms and has been in use for over 15 years. The safety and efficacy of CRLM ablation has been demonstrated in randomised trials but large and prospective real-life data on effectiveness of microwave ablation is still lacking.
Data will be collected prospectively from medical centres throughout Europe via an electronic data capture (EDC) system. The primary objective is to assess the effectiveness of microwave ablation performed with the Emprint device in controlling colorectal metastatic tumours in the liver.
The CIRSE Emprint Microwave Ablation Registry is funded by a grant provided by Medtronic.
- Local tumour control 12 months after treatment on a per lesion basis
- Adverse events and toxicity
- Overall survival
- Overall disease-free survival
- Hepatic disease-free survival
- Time to untreatable progression by thermal ablation
- Systemic cancer therapy vacation
- Quality of life
- Economic aspects
|Phillipe L. Pereira (Co-Chairperson)||SLK Kliniken Heilbronn/DE|
|Thierry de Baère (Co-Chairperson)||Institute Goustave Roussy/FR|
|Reto Bale||Universitätsklinik Innsbruck/AT|
|Alice Gillams||The London Clinic/UK|
|Nahum Goldberg||Hadassah Medical Center/IL|
|Thomas Helmberger||Städtisches Klinikum München/DE|
|Martijn Meijerink||VU Meidisch Centrum/NL|
|Franco Orsi||European Institute of Oncology Milan/IT|
|Theo Ruers||Cancer Institute of Amsterdam/NL|
|Stefan Stättner||Salzkammergut Klinikum Vöcklabruck/AT|
|Thomas Vogl||Universitätsklinik Frankfurt/DE|